Clinical trial · no report yet · Phase 3
SOHO-02
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- NCT06452277 ↗
- Recruiting
- Bayer
- 32 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 12 | |
| X threads | 12 | |
| Podcasts | 8 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Advanced Non-small Cell Lung Cancer, HER2 Mutation
- Interventions
- Sevabertinib; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed
- Arms
- Sevabertinib · Experimental
- Standard of care (SoC) · Active comparator
- Enrollment
- 555 (estimated)
- Primary outcomes
- Progression free survival (PFS) per RECIST 1.1 as assessed by BICR
- Sponsor
- Bayer
- Start
- Aug 28, 2024
- Primary completion
- Oct 28, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06452277 · updated Sep 23, 2026